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Running the gauntlet to improve 
patient care
This supplement is the result of a gauntlet 
thrown down, and picked up, during a dinner 
in London just over a year ago. The gauntlet 
thrower was Don Berwick, president of the 
Institute for Healthcare Improvement in Boston. 
What, he asked, was the BMJ Publishing Group 
really for? What were we trying to achieve? In 
reply, I and our chief executive, Stella Dutton, 
were quick to quote the BMJ’s mission, which 
ends with the crucial words “to improve 
outcomes for patients.” Fine, said Don, but how 
about being more specific: which outcomes, 
what patients, by how much?
We took his suggestion seriously. Why not 
target a few important healthcare problems, 
taking a quality improvement approach 
and focusing on the evidence on how to 
make a difference in these areas? But how 
to choose which issues to tackle among 
the many millions of pressing healthcare 
challenges facing the world? We turned in the 
first instance to BMJ readers. In May 2007 
we asked you to tell us what information was 
most needed to improve the quality of care of 
patients in clinical practice. From your many 
rapid responses we harvested more than 200 
ideas. After categorising these and matching 
them against the priorities of national and 
international bodies, we created a shortlist 
of 12. With the help of an expert panel (see 
http://makingadifference.bmj.com) we cut 
these down to six.
Inevitably the choice of topics is subjective 
rather than scientific, but the six we have 
ended up with are interesting. Several turn the 
spotlight on areas that are less than glamorous 
and are perhaps all too often passed over, even 
as their impact on individual lives and society 
increases. Two topics deal with problems of 
old age: multiple illness and adverse drug 
reactions. Two deal with palliation: of chronic 
pain and in dying from non-malignant disease. 
The remaining topics deal with two very 
different but serious and growing public health 
challenges: drug resistant infections in the 
developing world and excessive drinking in 
young women. You will no doubt find important 
gaps in what we have chosen. But if this 
initiative proves useful we can expand it further.
On each of the six topics we’ve invited 
leading commentators to write the pairs 
of articles that make up this supplement. 
One article in each pair aims to describe 
the importance of the problem in terms of 
its health and societal impact. The other 
looks at the available evidence on quality 
improvement initiatives to tackle the problem. 
Perhaps inevitably, several of the quality 
improvement articles conclude that the 
evidence is inadequate and more research is 
needed, but the authors do lay out what they 
think are the priorities for future research. 
One key priority is to develop new and better 
research methodologies for evaluating quality 
improvement initiatives.
We need to choose one or two of these topics 
to focus on over the next year, on which we will 
create and compile content across the BMJ 
Group’s portfolio of products: the BMJ, BMJ 
Journals, Clinical Evidence, Best Treatments, 
and BMJ Learning. How will we know whether 
we have made a difference? We probably won’t 
in any scientific sense. But we 
will be looking for ways to 
evaluate the effect of the 
initiative. On this, as 
well as on the topics 
themselves, we would 
welcome your thoughts.
Fiona Godlee, editor, BMJ 
fgodlee@bmj.com
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committed to improving the quality of care received by patients in hospital. NCEPOD does this by 
undertaking confidential surveys, publishing reports that highlight remediable factors in the care of 
patients. NCEPOD’s remit extends across surgery and medicine and it is the valued contribution of all 
the clinicians and hospitals involved that ensures the quality of the reports produced.
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A shrinking window of opportunity
Around the world an estimated 10 million children 
under the age of 5 years die each year, the vast 
majority (90%) in a mere 42 countries. Of the 
major causes of death among children, infections 
such as newborn sepsis, diarrhoeal disorders, 
pneumonia, meningitis, and malaria are major 
killers. While much is known about the role that 
poor availability of interventions has in childhood 
morbidity and mortality in developing countries, 
much less is known about the contribution of 
antimicrobial resistance—but it is likely that the 
contribution of resistant infections is significant. In 
a prospective study of 1828 children with signs of 
systemic infections in Tanzania, the mortality from 
Gram negative bloodstream infection (44% of the 
deaths) was more than double that from malaria 
(20%) and Gram positive bloodstream infections 
(17%), and antimicrobial resistance was found to 
be a significant risk factor for mortality. A literature 
review has underscored the importance of hospital 
acquired resistant bacterial infections among 
newborn infants in developing countries.
The emergence of antimicrobial resistance 
is recognised as a major contributor to excess 
morbidity and healthcare costs in developed 
countries. In poorer countries, limited laboratory 
facilities and the lack of robust, population based 
surveillance systems has meant that information 
on the effect of antimicrobial resistance on health 
outcomes is restricted to a small number of 
infections. Emerging drug resistance in malaria, 
recognised for many years, has now resulted 
in many traditional drugs such as chloroquine 
becoming completely ineffective. An evaluation 
of trends in malaria treatment in sub-Saharan 
Africa has shown that continuing use of ineffective 
chloroquine treatment has contributed to excess 
malaria mortality. The case fatality rate for malaria 
fell as an increasing proportion of children received 
an effective treatment regimen: adjusted malaria 
case fatality rates were 5.1% in 1992 and 3.3% 
in 1994, and the corresponding percentages of 
children who received effective therapy were 85% 
in 1992 and 97% in 1993-4.
The increasing resistance of Streptococcus 
pneumoniae and Haemophilus influenzae to 
drugs has an effect on pneumonia mortality 
that is less well recognised, largely because of 
the difficulty in isolating the organisms from 
the bloodstream. In a prospective study of 
children in 5000 Bangladeshi urban households 
who had invasive pneumococcal disease, the 
Certain principles of effective quality improve-
ment interventions are universal. Relevant 
stakeholders must believe that it is worth while 
to remedy the deficiency in quality, that the 
benefits of change outweigh the costs, and that 
change is possible. The threat of antibiotic resist-
ance and its coevolution with particular patterns 
of antibiotic use are also universal. 
Unfortunately, the public health agendas of 
few countries have prioritised the problem of 
antibiotic resistance. This is especially true in 
less developed countries, where antibiotics are 
often overused and misused by formal and 
informal healthcare providers and by patients, 
who are often able to obtain antibiotics without 
a prescription. Few policy makers, few mem-
bers of the general public, and unfortunately 
too few medical schools and health profession-
als recognise the urgency and implications of 
the problem. Instead, pharmaceutical policies 
often focus on scaling up and ensuring access 
to drugs, including broad spectrum antibiotics, 
without considering rational use.
What will really help to create change and fos-
ter effective quality interventions to tackle resist-
ant infections in developing countries? Strategies 
in such countries require changes at the levels of 
policy, the institution (including healthcare pro-
viders), and the individual.  Quality improve-
ment strategies to improve the behaviour of 
providers and patients do exist in developing 
countries, but their success depends on govern-
ment and stakeholder support.
To increase government and stakeholder 
involvement and accountability, it is impor-
tant to establish national programmes that 
publically report rates of antibiotic use and 
resistance. Although the World Health Organi-
zation (WHO), the Pan American Health 
Organization, and others have promulgated 
useful recommendations for hospitals and 
communities around the world to combat anti-
microbial resistance, few developing countries 
have been able to implement these recom-
mendations fully.  When resources are limited, 
assuring access to drugs tends to overshadow 
the quality of their utilisation. The interna-
tional community should partner with devel-
oping countries to perform the initial cycles 
of measurement and to design systems to link 
the data with information to the public on the 
effect of the problem on population health, 
personal health, and the economy. Such meas-
urement should occur across several countries 
in close proximity to harness “peer pressure” 
and  foster better practices.
m a k i n g  a  d i f f e r e n c e
drug resistant  
infections in  
poor countries
Resistance to drugs in many 
common childhood infections 
is a growing problem in the 
developing world, says Zulfiqar 
Bhutta. Effective programmes 
to combat resistance are within 
reach in developing countries, 
argue ralph gonzales and 
colleagues, but we must move 
swiftly
Longer versions of all the articles 
in the Making a Difference 
supplement, including references 
and figures, are at  
http://makingadifference.bmj.com
A major burden on children
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Performance measurement and account-
ability are potent inducers of behavioural and 
systemic change in organisations. For example, 
accreditation agencies and funders now require 
hospitals in the United States to publically 
report performance and outcome measures, a 
policy that has triggered an explosion of quality 
improvement activity in US hospitals. An excel-
lent template for the annual measurement and 
comparison between countries of consumption 
of antimicrobials and resistance rates has been 
developed by the GRACE project in Europe 
(www.grace-lrti.org/portal/en-GB). Similar uti-
lisation and resistance profiles for developing 
countries are needed, and efforts are under way 
to accomplish this in Latin America through a 
partnership between research institutions, gov-
ernment agencies, and WHO.
Many lessons from quality improvement 
interventions in health care in wealthier coun-
tries can be applied elsewhere. Various frame-
works and theories have been found useful for 
diagnosing contextual factors and developing 
strategies to change specific policies, organisa-
tional practices, and the behaviour of provid-
ers and individual consumers. For example, 
education and decision support, when part of 
a comprehensive effort, have been useful in 
HIV prevention, tuberculosis management, 
and tobacco control, as well as in appropriate 
antibiotic use. The literature also shows that 
quality improvement initiatives that lack local 
champions and stakeholder support will face 
formidable challenges to success.
Strategies that work in one place must be 
assessed for their applicability to other settings, 
and programmes must be tailored to countries’ 
unique circumstances. Formative research into 
social factors and practices in specific regional 
and local contexts, such as how the public and 
professionals make decisions to recommend, 
procure, and use antibiotics, is indispensable 
to achieve change. For example, we found 
that most patients (62%) purchasing antibiot-
ics in Mexican pharmacies without a prescrip-
tion reported acting on the recommendation 
of a clinician. Thus, in Mexico, education 
campaigns to reduce unnecessary antibiotic 
use must target doctors as well as the public. 
Nevertheless, educating the public is crucial, 
as patients often misuse antibiotics regardless 
of whether they were bought over the counter 
or were prescribed.
In developing countries, access to antibiotics 
without a prescription is commonplace. Here 
the priority should be to change regulatory 
 policies related to antibiotic procurement and 
to enforce these policies. This includes creat-
ing an infrastructure for surveillance, commu-
nication, and effective sanctions. For example, 
in Chile a mass media campaign preceded 
 enforcement of regulatory measures making 
antibiotics available by prescription only, 
resulting in a 35% decrease in antibiotic con-
sumption. It may be useful to emphasise the 
repercussions that are unique to antibiotic use: 
in contrast to other drugs the consequences of 
an individual using antibiotics extend to that 
person’s family and community. Finally, we 
need to use data and the media to challenge 
the perception that providing access to antibi-
otics without a prescription somehow helps to 
compensate for the lower access to doctors in 
poorer countries.
The window of opportunity for combating 
antibiotic resistance continues to shrink. Much 
work remains to be done in most countries, but 
particularly in developing countries. We believe 
that effective programmes to tackle resistant 
infections are tenable and within reach of the 
constrained resources of developing countries. 
The major barriers are the political and public 
will to set up the systems that can bring about 
change. Partnerships among national and inter-
national stakeholders will help.
ralph gonzales professor of medicine (epidemiology and 
biostatistics), Clinical and Translational Sciences Institute KL2 
Multidisciplinary Career Development Program, University of 
California, San Francisco ralphg@medicine.ucsf.edu
kitty k corbett professor, Faculty of Health Sciences, Simon 
Fraser University, Burnaby, British Columbia 
Veronika Wirtz  lecturer,  anahi dreser researcher, Center of 
Health Systems Research, Instituto Nacional de Salud Publica, 
Morelos, Mexico
incidence of the disease was 447 episodes per 
100 000 child years, and the rates of resistance to 
penicillin, co-trimoxazole, chloramphenicol, and 
ciprofloxacin were, respectively, 3%, 82%, 15%, 
and 24%.
Such evidence of the failure of co-trimoxazole 
has led to the recommendation to use amoxicillin 
to treat pneumonia in primary care settings, but 
as yet few health systems in the poorest countries 
have the extra funds needed to implement these 
recommendations widely. This is akin to the need 
for combination therapy for effective malaria 
treatment and to second line treatment for drug 
resistant tuberculosis in children, both looming 
realities in public health systems in sub-Saharan 
Africa. In South and South East Asia a major burden 
of childhood bacteraemic infections is related 
to typhoid fever, as well as the infections listed 
above. Over the last two decades the prevalence of 
multidrug resistant typhoid has steadily increased 
in Asia, and with the widespread use of generic 
ciprofloxacin and cephalosporins resistance 
to these second line antibiotics has steadily 
grown. Increasing antimicrobial resistance 
results in a much higher economic burden on 
the health systems of poor countries, because of 
the higher likelihood of treatment failure and of 
complications associated with such infections.
Several factors are associated with the rise of 
resistance to common infections in developing 
countries, including the global spread of drug 
resistant clones as travel becomes easier 
and local antimicrobial pressure on common 
organisms. This second factor may be related 
to inappropriate prescribing of antibiotics, the 
unregulated availability over the counter of 
these drugs, and (for reasons of affordability) 
inappropriate dosages and duration of 
treatment. 
Increasing public awareness, improving 
standards of care, and the appropriate regulation 
of the use of such antimicrobials are all important 
steps. A recent evaluation of the effect of the 
Swedish national programme for the surveillance 
of antibiotic use and resistance and the 
implementation of rational antibiotic use showed 
that antibiotic use among outpatients fell from 
15.7 defined daily doses per 1000 people in 1995 
to 12.6 per 1000 in 2004. The largest reduction (by 
52%) was noted in children, with no measurable 
negative consequences on admission rates for 
common upper respiratory infections. However, 
examples of successful application of such 
interventions in developing countries are few.
What are the main challenges with regard to 
antimicrobial resistance in common childhood 
infections in developing countries? We need better 
information systems defining the magnitude 
of the problem and training programmes to 
optimise treatment with antibiotics. As we need to 
balance antibiotic “access” as well as “excess,” 
measures to regulate antibiotic availability must be 
accompanied by strengthening workforce capacity 
and drug supplies in dysfunctional health systems. 
The crisis of increasing antimicrobial resistance 
to serious and common childhood bacterial 
infections is a reality in developing countries, and 
solutions are urgently needed.
Zulfiqar a Bhutta professor and chairman, Department of 
Paediatrics and Child Health,The Aga Khan University, Karachi 
zulfiqar.bhutta@aku.edu
antimicrobial resistance 
results in a much higher 
economic burden on the health 
systems of poor countries
drug resistant infections in poor countries 
Never had it so good?
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Adapting what is known
What does it mean to be old? What is the 
relation between ageing and illness? How 
does the subjective experience of multiple and 
compounding illnesses relate to the medical 
model and the taxonomy of disease? These 
questions become more pressing as an ever 
greater proportion of the population survives 
into extreme old age, and as the postwar baby 
boomers—those who “never had it so good,” 
as Harold Macmillan put it—begin to draw 
their pensions.
Globally the proportion of people aged ≥60 
years is growing very fast. It is expected that by 
2025 a total of about 1.2 billion people will be 
in this age group. By 2050 this number will have 
risen to two billion, 80% of them in developing 
countries. The older population itself is also 
ageing. Currently 69 million people are aged over 
80, and although this age group now accounts 
for only 1% of the world’s population (and 3% 
in developed countries), it is the fastest growing 
segment of the population.
The World Health Organization and many 
national governments are promoting the concept 
of “active ageing,” which portrays ageing as a 
positive experience and promotes continuing 
participation in social, economic, cultural, 
and civic activities. The concept is based on 
rights rather than on need and seeks to move 
away from a view of elderly people as frail and 
dependent. All this is to be applauded, but it may 
conceal a worrying reluctance to acknowledge 
the inevitable reality of death and dying. All 
bodies must die and find ways of doing so.
Age is a fundamental cause of disease, 
working through a multiplicity of causal 
pathways to generate multiple risk factors and 
multiple disease outcomes. All clinicians are 
familiar with this process, by which treating one 
disease in a frail, older person often means that 
symptoms reappear through another pathway. 
As the treatment of disease slowly becomes 
more effective, an ever greater proportion of the 
population survives with multiple compounding 
chronic diseases. The commonest of these 
are cardiovascular disease, stroke, diabetes, 
cancer, chronic obstructive pulmonary disease, 
musculoskeletal conditions, and mental illness 
(including dementia), occurring in many different 
combinations. The orthodox medical view is 
that these are distinct and definable conditions 
each of which carries a different prognosis and 
Multiple health problems are not unique to 
older persons; they are, however, more preva-
lent in this group. Furthermore, as a person 
ages, what was once a reasonable choice in 
treatment may be less appropriate, even 
harmful. In making clinical decisions about 
the health of older patients and in quality 
improvement for managing care, what are the 
trade-offs between benefit and risk? What are 
the opportunities for, and the barriers against, 
putting such knowledge into practice?
A 78 year old woman with complex 
health problems visits her doctor. Although 
in younger patients clinical recommenda-
tions may include screening mammography 
or intensive control of diabetes, this woman 
may not actually live long enough to benefit 
from these interventions. The issues that are 
most important to her may bear little rela-
tion to the bioclinical problems her doctor 
has been trained to diagnose and treat. Col-
laborative decision making by clinicians and 
older patients such as this woman is almost 
always made in a grey zone of unavailable 
evidence and divergent expectations. Yet 
tools are becoming available to help weigh 
the trade-offs between treatment benefits and 
competing risks. As these tools become more 
sophisticated and easier to use in the everyday 
clinical setting, they will help in clarifying the 
choices that must be made by older patients 
with multiple health problems.
The environment in which care is offered 
and decisions made—the system of “usual 
care”—is often bad for health. Its toxicity may 
be a consequence of too many health workers 
providing fragmented care, too many drugs 
having adverse side effects, or too much inten-
sive treatment leading to dangerous compli-
cations. And usual care suffers by being fast 
paced, reimbursed according to volume, and 
focused too much on what the matter is with 
the patient, rather than what matters to the 
patient. Many alternatives to this usual care 
are better, but most of these add additional 
workforce—nurses, case managers, “coaches,” 
and “teams”—in bewildering combinations 
called disease management, case management, 
transition management, and geriatric evaluation 
and management.  Other effective alternatives 
to usual care, such as routine telephone calls 
to the patient from an identified primary care 
clinician, need no additional workforce.
That there are so many things wrong with 
the usual care and so many ways to improve 
it raises an obvious question: why hasn’t qual-
m a k i n g  a  d i f f e r e n c e
Multiple health 
problems in 
elderly people
Longer versions of all the articles 
in the Making a Difference 
supplement, including references 
and figures, are at  
http://makingadifference.bmj.com
With ever increasing pressure 
on doctors’ time, iona Heath 
wonders whether primary care 
really meets the needs of elderly 
people at all, while John Wasson 
suggests ways for doctors to 
improve the care of older patients 
that don’t require extra resources 
or staffing
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requires different treatment. However, people 
who live with multiple diseases, physical and 
mental, experience them simultaneously and 
inseparably. The patient with diabetes and 
depression and congestive cardiac failure 
does not have these conditions in separate 
compartments of her life. She has all three 
inseparably and, if she is also lonely and 
frightened, all of this is a single condition.
The problem is that in health care the 
specialist medical view predominates. And, as 
a direct result, multiple diagnoses lead almost 
inevitably to polypharmacy as each condition 
is treated in perverse isolation from the others. 
Research findings are extrapolated from younger 
age groups and interpreted overoptimistically 
in the context of what inevitably are limited life 
expectancies. As a direct result, older people are 
taking an ever increasing number of prescribed 
drugs, but because of diminished physiological 
reserve they are also more susceptible to adverse 
drug reactions and interactions. Nevertheless, 
the all too easy accusation of age discrimination 
means that the limited time available for older 
people to derive clinical benefit is not seen as 
a legitimate reason for “underprescribing.” 
Systems of “quality improvement” that involve 
payment for performance, such as the UK 
Quality and Outcomes Framework (QOF), 
apply standards with no allowance for age 
and systematically encourage overtreatment 
of hypertension and type 2 diabetes, to 
the detriment of patients. Many preventive 
treatments in old age may simply change the 
cause of death and not its date. The energetic 
treatment of cardiovascular risk factors is 
effective in reducing cardiovascular mortality but 
does not prolong life and increases the likelihood 
of a diagnosis of cancer or dementia.
Old people themselves have different 
priorities and can find the epidemiological 
perspectives of healthcare professionals to be 
intrusive and inappropriate. Most elderly people 
are very aware of death and know that it must 
be faced and negotiated: “The big event of old 
age—the thing which replaces love and creativity 
as a source of drama—is death” (the author 
Diana Athill).
Many frail older people have a rapidly 
diminishing appetite for technological health 
care and a proportionately increased need for 
sensitive, gentle, hands-on physical care: a 
need that is easily compromised by the very real 
fear of becoming a burden. At present, medicine 
seems to have limited means of marking 
this transition, but such means are urgently 
needed, because the continuing emphasis on 
individual diseases leads, usually inadvertently, 
to undertreatment, overtreatment, or 
mistreatment—and often all three.
Tragically, the global trends of 
commodification, privatisation, and 
fragmentation in health care mean that the 
dimensions of care most needed by frail elderly 
people become less and less accessible. Yet 
multiple illnesses can be coherently managed 
only by a personal generalist physician who 
is able to provide continuity of care for the 
patient’s whole experience of illness, while at the 
same time remaining alert to those diagnostic 
possibilities that are readily remediable. But how, 
within a market system, can unprofitable need 
for time intensive and hands-on personal care 
from a known other ever be given commensurate 
priority?
iona Heath general practitioner 
Caversham Group Practice, Kentish Town, London  
iona.heath@dsl.pipex.com
ity improvement already resulted in better 
usual care for older persons with multiple 
health problems?
One reason commonly given for the per-
sistence of poor care is that most studies of 
successful interventions for elderly patients, 
when compared with usual care, have not 
provided clear evidence of cost savings. 
However, saving costs seems a poor reason 
for not improving care, and indeed many of 
the attributes of good quality care may not 
require extra staff or money. In fact, within 
the range of usual care about a fifth of older 
patients with multiple health problems are 
already receiving the high levels of access, 
continuity, communication, and self man-
agement that are associated with successful 
alternatives.
The fact that these crucial attributes of qual-
ity care are already available to some patients 
raises a second question: can this high qual-
ity care be generalised to more patients? 
An  affirmative answer to this question is 
provided by one innovative US example 
of a quality improvement project: an online 
collaboration involving a group of primary 
care practices across the country  (www.ideal-
medicalpractices.org). In these practices, the 
percentage of older patients with complex 
health problems who are attaining attributes 
of high quality care as listed on the website 
is more than twice that in non-participating 
practices, even though they receive no spe-
cial reimbursement.
The thrust of future research into quality 
improvement for older patients with multiple 
health conditions should be directed towards 
two objectives. The first is research into 
how to adapt and adopt what is known. The 
existing literature on quality improvement 
demonstrates numerous ways to improve 
health care for these patients through 
timely assessment of “what matters,” easy 
access to care, continuity of care with an 
identifiable clinician, and understandable, 
relevant information and support for con-
dition management and collaborative deci-
sion making. Although no particular setting, 
patient population, or disease mix will be 
identical to those reported in the published 
literature, many essential elements are con-
stant. For example, it is not surprising to cli-
nicians that their patients’ confidence in self 
management, financial status, and manag-
ing pain and psychosocial problems affects 
their healthcare outcomes. What is surpris-
ing is that clinicians don’t systematically 
evaluate these factors when assessing older 
patients and placing them into categories for 
the delivery of planned care. Technologies 
and methods are already freely available to 
help busy health professionals capture these 
 valuable opportunities.
The second area is research into how to 
overcome the most conspicuous barrier to 
the improvement of care: the current health-
care culture. The current culture induces dys-
functional workforce expectations, unwanted 
variation in practice patterns, ineffective 
training venues, counterproductive payment 
incentives that are often based on inappro-
priate measures, and excessive technological 
imperatives.  Only in a very few clinical prac-
tices are measures of “what matters” to the 
patient really at the centre of care. At a mini-
mum, the prevailing culture has to change 
to enable breathing room from oppressive 
volumes of consultations and paperwork so 
that the few motivated health professionals 
implementing patient centred, collaborative 
care can become the many.
John H Wasson professor of geriatrics
Dartmouth Medical School, Lebanon, New Hampshire
John.H.Wasson@dartmouth.edu
the prevailing culture has  
to change to enable breathing 
room from oppressive 
volumes of consultations  
and paperwork
Never had it so good?
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medical milestones
Reducing harm through quality 
improvement
Are we now seeing the undesirable 
consequences, for instance in drinking and 
smoking habits, of female emancipation? As 
women quite rightly seek greater opportunities 
for equality in the workplace and in other 
aspects of life, we see signs of them falling prey 
more and more to so called lifestyle diseases. 
Young women are all too commonly seen 
huddling outside enjoying a cigarette; and while 
lung cancer rates fall overall, they continue to 
rise in women. 
Women are also conspicuously heading for 
equality in their drinking habits. In the most 
recent British general household survey, 42% of 
men and 39% of women aged 16 to 24 years had 
exceeded safe recommended daily limits in the 
previous week, with over half of those drinking 
heavily or “bingeing.” The United Kingdom has 
the heaviest drinking young women in Europe, 
nearly 40% of whom admit to having drunk six or 
more units in one session in the previous week.
Does it matter that our young women are 
having fun? Most get away without harm and 
will probably settle down. But those who do 
not escape harm may have their life changed 
fundamentally under the influence of alcohol. 
Most first consensual sexual experiences and 
unwanted pregnancies occur in this way, and 
the distinction between rape and sex regretted 
the next day can become blurred when women 
are drunk. Genitourinary clinics see drink as the 
biggest factor in unprotected sex and sexually 
acquired infections. Some young women will 
be scarred for life through drunken brawls and 
arguments. In Scotland about 30% of women 
committing violent crime are drunk.
Of course, the victims of accidents need not 
be drunk themselves: alcohol is responsible 
for much third party or collateral damage. In 
England and Wales, over half of victims of 
violence perpetrated by a stranger judged 
the attacker to be under the influence of 
alcohol. This is particularly an issue in 
domestic violence, where again at least half of 
perpetrators are likely to have been drinking. 
It is remarkable how damage to the health of 
third parties was such a tipping point for public 
opinion on the issue of smoking in public 
places, yet alcohol is hugely more serious in 
this regard.
Teenage girls and young women are unlikely to 
be receptive to arguments about serious organ 
The concept of harm reduction has evolved 
over nearly 90 years from its beginnings in the 
1920s, when it applied to drug misuse in adult 
populations. Applying the concept to adoles-
cent groups at risk is relatively new, requiring 
that the concept be adapted appropriately. 
Adolescent harm reduction spans a wider 
array of harmful behaviours than are discussed in 
the literature: substance misuse, multiple sexual 
partners, violence and weapon carrying, non-use 
of helmets when cycling, skating, or snowboard-
ing, riding with a driver who has been drinking, 
and suicide plans. But the main contributor to 
death from injuries in people in the United States 
under the age of 21 is underage drinking.
Young women are “outdrinking” their male 
counterparts of the same age and are more likely 
to experience adverse health consequences. Such 
behaviour may undermine neurological brain 
development, predispose to adult dependency, 
and increase mortality. The strong association 
between drinking and having multiple sexual 
partners “underscores the need to educate young 
people about the effects of alcohol on partner 
choice and the risk of infection with sexually 
transmitted diseases,” as one study put it.
 Harm from drinking often involves oth-
ers; among young women this other will often 
be an unborn child. Fetal alcohol syndrome 
is the leading cause of brain damage in chil-
dren in the United States. Young girls are now 
drinking and smoking like boys and are more 
likely to be depressed and to attempt suicide. 
In primary care the complexity of these risky 
behaviours among young people often goes 
undetected, owing to lack of time, of access 
to effective treatment, and of coordinated and 
adequately funded resources in the commu-
nity to reduce harm.
A growing number of patients with serious 
mental illness and substance misuse report 
being treated in primary care or emergency 
rooms. Despite the availability of evidence 
based treatment for these disorders, many 
patients and families do not receive effective 
treatment in real world settings. One strategy 
to help remove such barriers is to re-engineer 
the processes of care delivery, using an evi-
dence base of changes that lead to improve-
ments in the quality and efficiency of care.
Our organisation, the non-profit Intermoun-
tain Healthcare (http://intermountainhealth-
a k i n g  a  d i f f r e n c e
Not just a “lifestyle disease”
excessive  
drinking in  
young women
Longer versions of all the articles 
in the Making a Difference 
supplement, including references 
and figures, are at  
http://makingadifference.bmj.com
The growing problem of binge 
drinking among young women is 
one that must be dealt with at a 
societal level, says ian gilmore. 
Nevertheless, doctors can make 
a difference at an individual level, 
and Brenda reiss-Brennan 
and colleagues describe one US 
quality improvement intervention 
in primary care
BMJ | Making a difference | 26 april 2008 | VoluMe 336           953
damage in years to come, and so it is important 
to highlight dangers that are more immediately 
relevant to them. It is now apparent that fetal 
alcohol syndrome, where babies are born with 
severe brain damage and a typical physical 
appearance, is but one end of a spectrum (fetal 
alcohol spectrum disorders); and less obvious 
behavioural disorders such as attention deficit 
hyperactivity disorder may result from exposure 
to alcohol in the womb. Unfortunately exposure 
in early pregnancy is likely to be important, and 
so far no safe threshold has been identified. Thus 
the only safe advice is for women to avoid alcohol 
if they seek to become pregnant—tough advice 
where every celebration now seems to have 
alcohol at its core.
Alcohol misuse remains the most important 
cause of death from chronic liver disease 
(cirrhosis), the prevalence of which has grown 
startlingly in women, particularly in the 35-44 
year age group (sevenfold in the last three 
decades) but also in even younger women. 
This reflects the early age when heavy drinking 
starts. Particularly striking is the emergence 
of the syndrome of alcoholic hepatitis 
(not always associated with histological 
cirrhosis), where the patient is febrile, deeply 
jaundiced, and often has ascites and other 
features of decompensation of liver function. 
Histologically this can be indistinguishable 
from non-alcoholic fatty liver disease, and it 
has been suggested that alcoholic hepatitis 
may be a “double hit” of alcohol on top of 
a fatty liver, often associated with obesity, 
which would explain the rapid increase in the 
disease. Certainly the burden of harm is seen 
disproportionately in the most disadvantaged 
in society, a striking example of health 
inequality that remains unexplained.
What can be done to turn this tide of alcohol 
related health harm in young women? We 
know that telling them to behave better will 
not work. England’s national alcohol harm 
reduction strategy of 2004 relied heavily on 
voluntary partnerships with producers and 
retailers of drink, linked to public education 
and information. Sadly, these initiatives have 
palpably failed. This should not surprise 
us too much, because the best predictor of 
alcohol related health damage is per capita 
consumption, and it can hardly be in the 
industry’s interests to have falling sales. Hence 
we need to fall back on the tools that have an 
international evidence base: mainly price and 
availability. Alcoholic beverages have never 
been as cheap in real terms as they currently 
are—particularly those sold in off-licences and 
supermarkets—nor as available. 
Although approaches to increase price and 
reduce availability smack of the “nanny state,” 
it is simplistic to dismiss alcohol dependence 
and physical damage as lifestyle diseases, 
somehow down to the individual’s free choice 
and nothing to do with the state. Cheap drink is 
available and heavily promoted. Alcohol is our 
favourite drug, and it is distressing to see young 
women pressured into misusing it.
ian t gilmore president 
Royal College of Physicians of London 
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care.org/xp/public/about-intermountain/), 
became increasingly concerned that primary 
care resources were not being used effectively 
to treat patients with mental health conditions. 
Its medical leaders were influential in estab-
lishing the mental health integration (MHI) 
quality improvement programme. Over the 
last decade Intermountain has implemented 
MHI throughout 68 primary care clinics to 
identify patients with mental health or sub-
stance use disorders and to treat them and 
refer them to additional services. MHI makes 
available a clinical team and offers financial 
support to the primary care doctor. 
Sustained results show that MHI leads to 
improved functional status in patients and 
improved satisfaction and confidence among 
physicians in managing mental health prob-
lems as part of routine care at a neutral cost.
The primary care environment presents 
opportunities and challenges for reducing 
harm in young female drinkers. Alcohol 
dependence and underage drinking are com-
plex family health problems and are intensely 
personal and isolating issues for girls and 
young women. It is an opportune consultation 
in which teenagers’ health risks are uncov-
ered and wellness can be promoted. Although 
guidelines are available, the routine screening 
of young women for harmful behaviours var-
ies widely among primary care doctors.
The MHI assessment begins with a 
 common screening toolset administered by 
the family doctor, who determines, with the 
patient and family, the severity of the mental 
health concerns. It includes comprehensive, 
self reported measures of family history and 
relational support,  environmental stressors, 
use of substances, depression, anxiety, and 
bipolar and  attention deficit disorders.
The results determine whether the doctor 
continues routine treatment or triages the 
patient to the MHI psychologist, psychiatrist, 
or psychiatric nurse practitioner for prompt 
consultation. The team includes a nurse 
care manager, who provides support and 
feedback to the doctor, the patient, and the 
family. The care manager also provides edu-
cation and information and links the patient 
to community resources, if this will benefit 
the patient. 
The team members use harm reduction 
strategies to improve education and to pro-
vide treatment for alcohol misuse. They also 
facilitate the involvement of families and 
community resources in social support and 
reinforcement of abstinence. Strategies that 
are tailored to the preferences of patients and 
communities are more likely to result in posi-
tive behaviour change.
Intermountain’s MHI database identified 
123 263 patients across all age groups, 45% of 
whom were women (55 568). The data show 
that 25 945 girls and women aged <39 were 
being treated for substance misuse and that 
9107 had comorbidity of depression and sub-
stance misuse. Of those with a diagnosis of 
substance misuse, 420 (1.6%) were 18 years 
old or younger.
Adopting a harm reduction approach to 
help young female drinkers and their fami-
lies will require quality improvement inter-
ventions that provide institutional support for 
the primary care doctor to deliver care that 
is matched to the family’s and community’s 
social, financial, and cultural healthcare pref-
erences for wellness. Higher levels of social 
capital exert strong protective effects against 
alcohol misuse and harm.
Intermountain’s MHI programme is one 
example of a quality improvement interven-
tion that tackles social capital needs and such 
barriers as failed access and limited, frag-
mented treatment choices, which many fami-
lies face when trying to find help.
Brenda reiss-Brennan mental health integration director  
Brenda.reiss-brennan@imail.org
Wayne cannon medical director 
Primary Care Clinical Programs, Intermountain Healthcare
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Help and hope at the bottom  
of the  pile
Improving shared decision making  
in osteoarthritis
Chronic pain is common—but it isn’t sexy. 
People who through no fault of their own have 
their lives demolished by pain deserve our 
help. The Pain in Europe survey found that 
19% of almost 50 000 people questioned in 
a poll had chronic pain, defined as pain of at 
least moderate severity occurring almost every 
day for at least six months. One in five of these 
people had pain for more than 20 years, and 
most had pain for more than five years.
The main causes are back pain and arthritis, 
and the incidence of chronic pain increases 
with age. Our populations are ageing. In the 
United States the number of people aged 65 
years or older will have almost doubled by 2025 
to 63 million, from 37 million in 2006, and 
there will be a third of a million Americans over 
the age of 100 years by 2020.
Chronic pain has a substantial impact on 
quality of life. A Dutch study that analysed eight 
large datasets by quality of life factors ranked 
different medical problems. Musculoskeletal 
conditions (including arthritis and back pain) 
had the most severe effect on quality of life. 
This impact of everyday pain on quality of life is 
something that has yet to be fully appreciated 
by those who organise our health services and 
allocate resources.
Most normal or nociceptive pain can be 
managed with conventional painkillers, from 
paracetamol through to morphine, with the 
more powerful painkiller added for more severe 
pain. Most pains wax and wane, and flexible 
prescribing takes time to explain. Problematic 
pains include severe pain on movement with 
little pain at rest, leaving patients oversedated 
with painkillers when they are not moving. 
Problematic side effects of the drugs include 
drowsiness and constipation, a major burden 
for elderly people.
Perhaps the most testing pains are 
those that result from nerve damage, the 
neuropathic pains. Peripheral nerve damage 
from surgery, trauma, back pain, and the 
classic post-herpetic neuralgia, painful 
diabetic neuropathy, and trigeminal neuralgia 
often respond poorly to conventional 
painkillers and need the unconventional 
drug classes, the antidepressants and 
the antiepileptics. Titrating these drugs 
to maximise pain relief and minimise side 
effects is fiddly but necessary.
Common treatments for osteoarthritis include 
physiotherapy, bracing, pharmacotherapy, and 
joint replacement surgery. When treatments are 
proposed that increase the risk of harm (such as 
non-steroidal anti-inflammatory drugs, opioids, 
or surgery), patients’ values concerning potential 
benefits and harms need to be considered. How-
ever, clinicians find it difficult to judge patients’ 
values, which are also often based on unrealistic 
expectations. Therefore tools that improve the 
shared decision making process are important.
Shared decision making is a process in 
which the patient and clinician together reach 
an informed decision about the plan of care on 
the basis of the patient’s clinical needs, priori-
ties, and values. The clinician’s expertise lies in 
diagnosing and identifying treatment options 
according to clinical priorities; the patient’s role 
is to identify and communicate their informed 
values and personal priorities, as shaped by their 
social circumstances. 
Patient decision aids are tools that prepare 
patients for consultations by explaining options, 
quantifying risks and benefits, helping patients 
to clarify their values, and providing structured 
guidance in deliberation and communication. A 
review of 10 systematic reviews of patient deci-
sion aids found that they improved patients’ 
participation, increased their knowledge of 
treatment options, realigned their expectations, 
and improved the match between their values 
and subsequent treatment decisions. The aids 
also reduced the overuse of elective surgery (for 
herniated disc, for example) without apparent 
adverse effects on health outcomes. Another 
study showed the potential for patient decision 
aids to reduce inequalities among ethnic groups. 
The Cochrane inventory of patient decision aids 
(www.ohri.ca/decisionaid) uses international 
standards to rate their quality. Decision aids for 
osteoarthritis treatment are available online, in 
brochures, and on DVD.
In 2006, patient decision aids were accessed 
more than eight million times, mostly through 
the internet. Ideally, these tools should be linked 
to clinical care processes, but practitioners report 
several barriers to implementation: inappropri-
ate content for their patients; forgetting to offer 
them; inadequate time; content that was too 
complex or too simple; and cost. Practitioners 
are more likely to use patient decision aids if 
they have a positive effect on patients’ outcomes 
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Most chronic pain is managed with drugs 
in primary care. Obstinate pains—pains that 
resist drug control at acceptable levels of side 
effects—may need other treatment options, 
from injections through to a multidisciplinary 
pain management programme. The necessary 
skill mix includes nursing, psychology, 
drug expertise, and injection options and 
physiotherapy.
The imperative to provide this tier of 
expertise is humanitarian and economic. 
Patients with chronic pain who are managed 
poorly will bounce around the healthcare 
system, becoming more and more 
exasperated and consuming considerable 
resources. Well managed pain contains this 
excess use of resources, saving an estimated 
£1500 (€1900; $3000) per patient per year. 
Set against the background of the large 
economic burden of chronic pain, the cost of 
this tier of expertise is marginal.
An estimate of the financial burden of 
musculoskeletal illness in the United States 
argued for $50bn, and the indirect costs 
of back pain in the United Kingdom are 
estimated at £11bn. Certainly, chronic pain 
increased costs for payers by more than 
double, in comparison with matched controls 
without pain ($C4200 (£2070; €2600; 
$4100) versus $C1800 a year), an excellent 
Canadian database survey found. There are 
also financial implications for the person with 
the pain, reduced household income being 
the most obvious example.
No one thing will improve this situation. 
We need more and better basic research, the 
most tangible products of which are likely to 
come from the major drug companies. But 
there have been pitiably few new painkillers 
in the past 30 years.
Clinical research and practice are now much 
more likely to make a difference, helping 
to make existing evidence sensible and 
understandable so that people can use it. The 
evidence base in pain enables us to assess 
the relative effectiveness of treatments, for 
instance in nociceptive and neuropathic 
pain and indeed in migraine. This evidence 
does not dictate what analgesic to use for a 
particular patient but does help us to make 
choices about treatments on the basis of their 
effectiveness, propensity for harm, and cost.
Then there’s the provision of care. Chronic 
disease comes low on the political priority 
list, and chronic pain just gets forgotten. 
The burden for the sufferers, their families, 
and society is substantial and merits better 
treatment. 
The mark of a gracious society is how it 
treats those with least voice. That chronic 
pain puts people at the bottom of the pile 
is precisely why we should be agitating on 
their behalf for a fairer share of the medical 
resource cake.
Henry McQuay professor of clinical anaesthetics  
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or on the clinical interaction. Orthopaedic sur-
geons rated the content of patient decision aids 
for osteoarthritis treatments as good to excel-
lent and were motivated to use them to improve 
patients’ understanding but had concerns about 
interrupting the flow of clinic work.
Patient decision aids have been implemented 
successfully in specialist clinics in the United 
Kingdom and Canada and in specialist and pri-
mary care clinics in the United States.  Patients 
with osteoarthritis, for example, use decision aids 
together with balanced, evidence based informa-
tion on the treatment options and the likelihood 
of the benefits and harms of those treatments. 
The decision aids help patients clarify their val-
ues concerning benefits and harms by describing 
what it is like to experience them. Patients then 
complete a personal decision form, which elicits 
their knowledge, values, preferred option, and 
any unresolved “decisional needs” (for example, 
uncertainty about their preference, gaps in their 
knowledge of the options, lack of clarity of their 
values concerning benefits and harms, and sup-
port needs). This information is summarised on 
a “patient preference report,” which is sent to the 
clinician to “close the loop” on decision making 
with the patient. 
In Canada, patients on the waiting list for a 
surgical consultation are screened for eligibility 
by trained general practitioners or physiothera-
pists before they receive a decision aid and 
personal decision form. The Canadian patient 
preference report (see http://makinga difference.
bmj.com) lists clinical priorities as determined by 
self reported pain and functional limitations, the 
trained screener’s assessment of surgical prior-
ity, and the patient’s preferences and decisional 
needs. The report is paper based, but one author 
(NC) has developed a similar computerised 
report as part of the US Veterans Administra-
tion’s electronic patient health records.
Using the patient preference report together 
with patient decision aids has the potential to 
improve the clinical encounter and to provide 
the incentive that practitioners need to over-
come their resistance to using the aids. For 
example, when patients arrive at a surgeon’s 
consultation with their preference report, the 
surgeon can focus on issues of concern to the 
patient, such as fears of side effects of surgery. 
Thus the surgeon’s time will be used more effi-
ciently, and the care provided is more patient 
centred, so patients and practitioners are both 
more likely to be satisfied with the process.
Outcomes such as pain reduction and 
improved function cannot be the sole quality 
indicators in treatments that involve trade-offs 
between potential benefits and harms. In such 
treatment decisions, the quality of decision mak-
ing should be defined by how well the chosen 
treatment option matches the features that mat-
ter most to the informed patient. Patient prefer-
ence reports document decision quality as an 
indicator of the shared decision making proc-
ess. In addition to monitoring postoperative 
complications such as infections, these reports 
can be used by quality improvement teams to 
monitor the extent to which high quality deci-
sions are achieved and decisional needs met.
Patient decision aids prepare patients for 
making shared decisions concerning treatment. 
Patient preference reports that summarise 
patients’ clinical and decisional needs improve 
communication. With standardised measures 
and documentation of decisions, healthcare 
organisations can monitor and include deci-
sion quality as another indicator of the quality 
of their programmes.
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The challenge of safer prescribing
Patients over 65 years old bear the greatest burden 
of illness and thus are the greatest beneficiaries of 
drugs to prevent, ameliorate, or treat conditions. 
One of the most rapidly growing segments of the 
population, they consume an ever increasing 
proportion of all prescribed drugs.
For decades elderly people were excluded 
from randomised trials of many preventive drugs, 
reinforcing scepticism over whether they would 
benefit from treatment of conditions such as 
hypercholesterolaemia and hypertension. But 
elderly patients may benefit from such treatments 
at least as much as their younger counterparts. 
In fact, because of the higher prevalence of 
preventable disease in older patients, they often 
derive greater benefits from such prescribing than 
younger patients. 
For this reason, much primary care has 
shifted from the treatment of acute illness to the 
management—often pharmacological—of “risk 
states” in elderly people, including hypertension, 
hypercholesterolaemia, and osteoporosis, as 
well as diseases such as atrial fibrillation, heart 
failure, and diabetes. Solid evidence from clinical 
trials indicates that appropriate prescribing can 
substantially reduce the burden of preventable 
morbidity in these conditions. Although such 
concerns are traditionally seen as a problem of the 
industrialised world, they are rapidly becoming a 
major issue facing developing countries as well.
But this benefit comes at a price: the high 
prevalence of adverse drug reactions in older 
patients. The problem has several sources. 
One is the altered pharmacokinetic status of 
elderly people; they are less able to metabolise 
and excrete many common drugs, even in the 
absence of liver or kidney diseases. They may 
also have altered pharmacodynamic responses, 
with some receptor systems (such as those for 
opiates and benzodiazepines) having greater 
sensitivity with advancing age, and others (such 
as those for insulin) showing reduced sensitivity. 
Unfortunately, the under-representation of older 
patients (especially frail ones) in clinical trials 
makes it even harder for the prescribing doctor to 
prevent untoward drug reactions in older patients.
When an elderly person experiences an adverse 
drug reaction, it may be mistakenly attributed 
by the patient or doctor to a new disease or 
(even worse) the ageing process itself. Examples 
include the parkinsonian side effects of many 
antipsychotic drugs and the fatigue, confusion, 
Quality improvement for the care of older 
people has become a priority in many 
countries. Elderly people consume a large 
proportion of health care, including drugs, 
and evidence shows that prescribing to this 
group is often inappropriate. Inappropriate 
prescribing occurs in all care settings and 
at the transition between settings. Negative 
consequences include adverse drug events, 
higher costs for the patient and society, and 
impaired quality of life.
Specific approaches tailored to the needs 
of frail elderly people are needed. A recent 
review of ways to optimise prescribing to 
older people found that geriatric medicine 
services (involving a multidisciplinary team 
that includes a geriatrician and other health-
care providers with specialised geriatrics 
training), involvement of pharmacists in 
care, and computerised decision support can 
all improve the quality of prescribing to this 
group in different settings. 
Quality improvement strategies are more 
likely to be effective when there is direct 
interaction with the prescriber and when the 
strategies are provided at the time of prescrib-
ing. In nursing homes, involvement of nurses 
in strategies is another important factor. The 
effect of educational interventions is mixed, 
although the lack of training of doctors in 
geriatrics is often cited as a cause of inap-
propriate prescribing.
However, widespread diffusion of effec-
tive approaches has not yet occurred. As in 
many other fields, translating research into 
practice is a delicate task. In the domain of 
quality improvement for safer prescribing 
to older people, this is further complicated 
by a lack of strong data showing the impact 
of effective approaches on important health 
outcomes. Also, the question of who should 
meet the cost of such approaches is a mat-
ter for debate. And we lack data on the cost 
effectiveness of strategies. With regard to 
computerised decision support systems, we 
first need systems that have been tailored to 
elderly patients before they can be imple-
mented more widely.
It is important to take environmental 
barriers into account. Some barriers can 
be specific to the setting of care or even 
to the country of practice. For example, 
improving the quality of prescribing of neu-
roleptics in nursing homes is less likely to 
occur without an increase in staffing and 
resources. Direct contact with prescribers 
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or depression-like symptoms that can result from 
excessive use of heavily marketed psychoactive 
drugs. Elderly people are at special risk of 
such misattributions because of the pervasive 
cultural assumption that growing older brings 
with it a collection of inherent and inevitable 
disabilities. The problem is compounded by the 
slender preparation that most students receive in 
geriatrics and in clinical pharmacology. There is 
ample evidence of the clinical burden of iatrogenic 
illness in the elderly. Studies of US patients aged 
over 65 indicate that each year more than 180 000 
life threatening or fatal adverse drug effects occur 
in the outpatient setting, of which over half may 
be preventable. Another study attributed 6.5% 
of all hospitalisations in the general population 
to adverse drug events, a rate that is likely to be 
higher in elderly people.
Despite these gloomy realities, the most 
notable aspect of drug induced illness in 
elderly people is the most encouraging. Once 
recognised, a side effect of a drug is probably 
the single most reversible affliction in all of 
geriatric medicine. Usually, care of elderly people 
requires the management of conditions with a 
downward course. But discovering that a symptom 
is caused by a drug presents an uncommon 
opportunity to effect a total “cure” by stopping 
the offending prescription or lowering the dose. 
In our own practices we have often seen patients 
on a seemingly inexorable trajectory towards 
institutional care whose functional capacity was 
restored by thoughtful reassessment of their drug 
regimens. This has led to the useful if overstated 
recommendation that “any new symptom in an 
older patient should be considered a possible 
drug side effect until proved otherwise.”
As well as being alert to the possibility of new 
iatrogenic problems, it is also prudent to reassess 
a patient’s entire drug regimen at least twice a 
year, including categories often overlooked by 
patients and doctors: drugs bought over the 
counter and “nutraceuticals” such as herbal 
remedies or dietary supplements. Although these 
products are often devoid of therapeutic benefit, 
they can impose important toxicities, and their 
interactions with prescribed drugs are poorly 
understood. With growing use of the electronic 
medical record, we can expect that drug regimen 
review will increasingly be prompted by the 
computer in the course of routine care. In one 
computerised system for entering prescription 
orders, the system automatically checks all 
prescribed drugs and dosages against the age 
of the patient and recommends a lower dose or 
different drug if necessary.
Non-compliance with prescribed drug regimens 
can produce a different kind of drug related 
morbidity. In this “silent epidemic,” as much as 
half of prescribed drugs are simply not taken. 
Considerable morbidity results from this other 
kind of drug related illness in elderly people, in 
which potentially useful treatments are not taken 
or (because of misplaced therapeutic nihilism) not 
prescribed in the first place. 
Broader systems based and educational 
approaches are emerging to guide the evidence 
based use of drugs in older patients so as to 
reduce their burden of iatrogenic illness while 
ensuring that needed drugs are prescribed 
properly. Better attention to managing this benefit-
risk relationship will play an increasingly important 
role in maintaining and improving the health of an 
ageing population.
Jerry avorn professor of medicine javorn@medsoc.harvard.edu 
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(such as with a clinical pharmacist) is not 
always feasible in nursing homes, and this 
can decrease the efficacy of the intervention. 
In some countries pharmacists do not have 
access to patients’ records. Consequently, a 
quality improvement strategy that is effec-
tive in one care setting cannot be directly 
transposed to another without adaptation. 
The same applies to transposition between 
countries, because of differences in practice 
environments and culture.
Big improvements in communication at 
the interface between primary and second-
ary care are urgently needed too. Many 
adverse drug events result from problems 
with communication relating to manage-
ment of drugs during the transition between 
care settings. National online databases of 
drugs dispensed to patients (as in Denmark), 
to which all doctors and pharmacists have 
access, should help to tackle such problems. 
The same should apply to patient records. 
Such a challenge should be taken up at the 
national level, although of course steps must 
be taken to protect patients’ privacy. Better 
communication among prescribers to track 
changes in treatment and to record the 
reasons for those changes will also help to 
avoid the fragmentation of care. This aspect 
should be included in measures of quality 
 performance.
Quality improvement strategies for safer 
prescribing in older people must include 
shared decision making. The beliefs and 
preferences of older patients concerning 
treatment affect adherence and, in turn, the 
safe use of drugs.  Several recent studies 
have shown the importance of considering 
patients’ wishes, but many questions remain 
unanswered. 
The high prevalence of people with 
dementia and the need to involve carers 
in decisions complicate further the task 
of shared decision making. Furthermore, 
many prescribers are not familiar with the 
principles of shared decision making or are 
reluctant to engage in it because of the extra 
time needed. Therefore a huge amount of 
work needs to be done here, from research 
to implementation. Education and train-
ing programmes for prescribers should 
include sessions on communicating with 
patients and on involving them in  decisions. 
Health authorities should also consider 
including this dimension of care in quality 
 performance measures.
What are the most urgent of the unan-
swered research questions? We need more 
clinical trials that enrol frail elderly patients, 
to enhance our knowledge of the benefits and 
risks of treatments in this group. With regard 
to quality improvement strategies, we need to 
evaluate the effect of multifaceted approaches 
on important health outcomes and costs. This 
is a challenging task that will certainly require 
multicentre trials with large samples. 
It is important that quality improvement 
approaches are multidisciplinary in nature, 
use computerised decision support systems 
that are specific to this age group, and take 
the patient’s view into account. 
Meanwhile, national health systems 
should provide incentives for prescribers 
to  regularly review treatments, develop 
 information  systems to facilitate seamless 
care, and encourage the implementation 
of  multidisciplinary approaches including 
 geriatric medicine  services. Quality improve-
ment strategies need to be  customised 
to account for  differences in patients, 
 prescribers, and environmental factors.
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medical milestones
Reliable comfort and meaningfulness
We must apply the lessons learnt from cancer 
(often slowly and painfully) to the growing 
number of people now dying from non-
malignant illnesses. New theoretical insights 
into the trajectories of decline in a range of 
long term conditions—together with technical 
developments that aid the delivery of care in 
people’s own homes and the timeless clinical 
qualities of listening, compassion, empathy, 
and inspiring hope—mean that we now have 
the means to make a real difference to the 
lives of so many people in the throes of their 
final illness and to the lives of their loved ones. 
Getting end of life care “right” lies at the heart of 
what it means to be a civilised society, and thus 
prioritising this area needs no apologies.
In 2005 cancer was responsible for a relatively 
small percentage of deaths worldwide (13%), 
while other long term conditions caused 47%. By 
2030 the annual number of deaths around the 
world is expected to rise from 58 million to 74 
million, with conditions related to organ failure 
and physical and cognitive frailty responsible 
for most of this increase. Yet despite these rapid 
demographic changes, palliative care services 
typically still cater only for people with cancer.  For 
example, hospices in economically developed 
countries currently provide 90% of their care to 
patients with cancer. Moreover, people dying 
from cancer usually have needs lasting for weeks 
or months, whereas those dying from organ 
failure or old age often have unmet needs that 
extend over many months or years. It is little 
wonder, then, that people dying of the “wrong” 
condition and their carers, whether family, social, 
or professional, are increasingly frustrated by the 
major obstacles to accessing appropriate care.
The drive to extend palliative care beyond 
cancer has so far been hampered by a 
combination of factors: prognostic uncertainty; 
funding difficulties (in the United Kingdom 
influential cancer charities support  many 
hospices and outreach programmes); lack of 
palliative care clinicians with expertise in non-
malignant diseases; and a hitherto relatively 
weak evidence base in relation to appropriate 
models of care. Although the empirical evidence 
base remains weak, we do now have a good 
theoretical understanding of when and how to 
intervene in a range of conditions.
Prognostic uncertainty can and does hinder 
clinicians in thinking and planning ahead. Most 
To live well in the time left to them, patients 
with fatal chronic conditions need confidence 
that their healthcare system ensures excellent 
medical diagnosis and treatment, prevention of 
overwhelming symptoms, continuity and com-
prehensiveness of care, advance care planning, 
patient centred decisions, ands support for car-
ers. Hospices and palliative care have improved 
these dimensions of quality for people dying 
from cancer. Applying those insights to other 
fatal chronic conditions could greatly improve 
the last part of life, although the endeavour 
entails substantial challenges. 
End of life care for elderly people will have 
to last for a long time: being disabled enough to 
need daily help now continues for an  average 
of more than two years before death. Patients 
with non-malignant, long term illness are 
older and frailer than patients with cancer (as 
are their carers). Transfers between hospitals, 
nursing homes, and home care often engender 
delirium,  depression, falls, treatment errors, and 
pressure ulcers, in addition to the common hos-
pice problems of pain and loss. Entities that 
are often unfamiliar to hospices—such as social 
insurance programmes for poor people and dis-
ability transportation—will need to be partners 
in care.
How can we ensure reliable services for 
all in the last phase of life? Systematic qual-
ity improvement and policy reforms will offer 
reliable and efficient strategies if they focus on 
the three common patient trajectories: short 
decline typical of cancers; intermittent exac-
erbations and sudden death typical of organ 
system failures; and the slow dwindling course 
typical of frailty.
For gains to be achieved and sustained, qual-
ity improvement requires clear goals, appropri-
ate teams, ways to monitor progress, sequential 
testing of improvements, and the institution-
alisation of improved processes. Local quality 
improvement has a track record of success in 
correcting some shortcomings of ordinary care. 
These include improving pain prevention and 
treatment (such as by routinely responding at a 
patient’s home within a time period determined 
by the patient or a family member), developing 
and implementing advance care plans (decid-
ing whether to attempt resuscitation, for exam-
ple), and preventing and healing pressure ulcers 
(one quality improvement programme reduced 
the incidence of full thickness lesions by 69%). 
Quality improvement projects can reduce over-
treatment near the end of life, improve prognos-
tication and counselling by providing automatic 
a k i n g  a  d i f f r e n c e
palliative care 
beyond cancer
Longer versions of all the articles 
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and figures, are at  
http://makingadifference.bmj.com
Care for all at the end of life
scott murray and aziz sheikh 
say that the lessons learnt from 
palliative care for cancer need to 
be applied to other fatal conditions. 
Healthcare delivery that is tailored 
to the varying needs of patients 
with these diseases will be  
crucial in making a difference,  
says Joanne lynn
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patients with heart failure die when they are 
still expected to live for more than six months, 
and accurate prognostication is also virtually 
impossible in people with chronic obstructive 
pulmonary disease (COPD).  Although this 
uncertainty is frustrating for doctors, its very 
presence can be a basis for initiating end of life 
discussions.
Recent work is helpful in identifying critical 
events and stages when a palliative approach may 
be introduced. People with progressive chronic 
illnesses follow three characteristic trajectories 
(see figure on http://makingadifference.bmj.
com): a cancer trajectory, with steady progression 
and usually a clear terminal phase; an organ 
failure trajectory, with gradual decline punctuated 
by episodes of acute deterioration and eventually 
a seemingly unexpected death; and a trajectory of 
prolonged gradual decline (typical of physical or 
cognitive frailty).
Hospices provide excellent and accessible 
care to people with cancer but are not configured 
to address the needs of patients who don’t have 
cancer. So what can we do? A typical critical 
juncture in an organ failure trajectory, such 
as hospitalisation for acute heart failure or an 
exacerbation of COPD, should trigger a holistic 
assessment and care plan for the next stage 
of the illness. Practical models of care are now 
being formulated and tested to fit the other two 
trajectories. Some Scottish general practitioners 
are, for instance, documenting a care plan for 
every patient admitted to hospital with COPD. 
Clinicians are thus alerted to “change gear” from 
routine chronic disease management to a more 
personalised palliative care approach, while 
continuing active treatment. These trajectories 
thus help us consider what should be done to 
promote quality of life rather than focus on what 
can be done, which may lead to futile treatment. 
A strategic policy overview of these trajectories 
may also help services to consider all people with 
serious chronic illnesses equitably, rather than 
cancer “top slicing” care.
Palliative care for everyone underscores the 
need for anticipatory personalised care for all 
people with life threatening illnesses. Technical 
developments such as video conferencing 
and remote monitoring devices may help in 
realising this aspiration, but far more important 
are the medical vocation’s essential clinical 
skills—active listening, respecting autonomy, 
and empathic care—none of which depends 
on first world infrastructures. These can be 
implemented anywhere in the world, as long 
as health services respect the importance of 
clinicians and patients having time together, 
ideally in the context of a relationship that 
allows for personal continuity of care.
Facilitating a good death should be recognised 
as a core clinical proficiency, as basic as diagnosis 
and treatment. Death should be managed 
properly, integrating technical expertise with a 
humanistic and ethical orientation. We also need 
research into how best to identify, assess, and 
plan the care of all patients who are sick enough 
to die, and we need education that keeps alive 
our humanity and sense of vocation. This is an 
enormous challenge in politicised, market driven 
healthcare models but one that will make an 
important difference to those most in need.
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feedback to clinicians, and implement shared 
accountability and effective drug reconciliation 
throughout changes of care settings. 
Sustainable excellence requires supportive 
social policies. Practitioners working in trust-
worthy arrangements for delivering care must 
make a living. But powerful economic interests 
and social forces now encourage the oversell-
ing to patients and families of treatments with 
little chance of success. Citizens and clinicians 
must encourage political leaders to champion 
more appropriate policies, such as allocating 
healthcare payments to reward continuity and 
comprehensive primary care  and ensuring an 
adequate income in retirement for family mem-
bers who are carers.
Such reforms will be more efficient when 
they set out to match eligibility and service 
patterns to the three dominant patterns in the 
last phase of life. If palliative and hospice care 
are available only to those who die in a pre-
dictable way in a short time, most people will 
never qualify, because their timing of death will 
stay  uncertain until very close to the end of 
life. A short period of hospice care does meet 
the needs of many cancer patients, but people 
with heart and lung failure are better served 
by having a much longer period of support for 
self care and rapid response to help people at 
home in times of crises. In contrast, people with 
dementia or who are frail are often best served 
by having many years of support to carers in 
the family. Delivery systems that are tailored to 
the usual needs of these groups would enable 
clinicians to customise care plans to the prefer-
ences of individual patients and their families.
The combination of specific innovations 
from quality improvement, encouragement in 
the form of payment and regulatory policy, 
and services tailored to particular groups of 
patients is a powerful package for reform. In 
various forms, such a strategy is being pur-
sued in many places: the United Kingdom, 
Saskatchewan in Canada, and Sweden, and in 
the United States by Kaiser Permanente, the 
Veterans Affairs Health System, and Medi-
care’s Quality Improvement Organizations in 
each state.
Every clinical team can use quality improve-
ment to adapt its own care system to the needs 
of patients with fatal illnesses. For example, 
doctors can shoulder the burden of helping 
patients and families come to a realistic view 
of the outlook and to collaborate in making 
plans. Claiming to be sustaining hope, doctors 
often offer improbable treatment plans, falsely 
implying that all will be well if the patient and 
family go along with them. Instead, an hon-
est appraisal of the situation, the likely course 
of the illness, and the treatment alternatives 
would allow the patient, family, and clinicians 
to negotiate the priorities among various goals, 
the preferred strategy, and a timeframe for 
reconsideration.
The ageing of populations will greatly 
increase the number of sick and dying older 
people, while smaller families and reduced 
retirement security will shrink the number of 
available carers in the family. The coming cri-
sis is obvious. Policy makers and practitioners 
must learn to support family carers, and local 
quality improvement and innovation in govern-
mental policy are the right prescriptions.
The dying patient’s clinical care team must 
provide highly skilled diagnosis and treatment. 
Doctors must be able to promise to prevent 
pain and dyspnoea near death, for example. 
Specialist palliative care is well established in 
many countries, but palliative care skills among 
those professionals who serve most patients—
long term care nurses, home care teams, gen-
eralist physicians, and specialist physicians—lag 
far behind.
Joanne lynn medical officer  
Office of Clinical Standards and Quality, Centers for Medicare & 
Medicaid Services, Baltimore Joanne.lynn@cms.hhs.gov
local quality improvement 
has a track record of success in 
correcting some shortcomings 
of ordinary care
palliatiVe care Beyond cancer
Reliable comfort and meaningfulness
Care for all at the end of life
